ACOG

Business Context and Reporting Period

Company: Alpha Cognition Inc. (ACOG)
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended December 31, 2025
Business Overview: Alpha Cognition is a commercial-stage biopharmaceutical company focused on neurodegenerative diseases. Its primary asset is ZUNVEYL (benzgalantamine), an FDA-approved oral tablet for mild-to-moderate Alzheimer's disease, commercially launched on March 19, 2025. The company targets the long-term care (LTC) market with a specialized sales force. Additional pre-clinical programs include ZUNVEYL in combination with memantine for moderate-to-severe Alzheimer's, and ALPHA-1062 for mild traumatic brain injury (mTBI).

Key Financial Metrics (Year Ended Dec 31, 2025)

Revenue Breakdown: Product sales (net) were $6.79 million; Licensing revenue was $3.43 million (primarily from a $3.0 million upfront payment from CMS International for Asian rights).

Cash Flow: Net cash used in operating activities was $20.38 million. Net cash provided by financing activities was $38.21 million, driven by public offerings and warrant exercises.

Material Changes vs. Prior Period

• Revenue Generation: The company transitioned from zero revenue in 2024 to $10.22 million in 2025, driven by the commercial launch of ZUNVEYL and the CMSI licensing agreement.
• Expense Growth: Selling, General, and Administrative (SG&A) expenses surged 263% to $29.08 million, reflecting the build-out of a commercial sales team, marketing, and regulatory costs. Research and Development (R&D) expenses decreased 52% to $1.87 million as the focus shifted to commercialization.
• Derivative Liabilities: The company recorded a gain of $88,155 on the change in fair value of warrant liabilities in 2025, compared to a loss of $3.16 million in 2024.
• Capital Raising: The company completed a $50 million IPO in November 2024 and a $35 million public offering in October 2025, significantly bolstering liquidity.

Guidance, Outlook, and Risks

Outlook: Management believes existing cash ($66.1 million) is sufficient to fund operations and commercialization through at least the next 12 months. The company aims to achieve operating profitability by 2027, contingent on successful execution of the commercial plan in the LTC market and not advancing pipeline compounds without external funding.

Key Risks:

• Commercialization: Success depends on payer coverage, formulary placement, and physician adoption in the LTC sector. High patient discontinuation rates of existing Alzheimer's therapies present an opportunity but also a challenge for retention.
• Supply Chain: Manufacturing relies on a single vendor in Taiwan for the active pharmaceutical ingredient (API) and a single U.S. vendor for tablet production, creating supply chain concentration risk.
• Internal Controls: The company identified a material weakness in internal controls over financial reporting regarding the accounting of warrants and stock option liabilities (specifically CAD-denominated options). Remediation is in progress.
• Regulatory: ZUNVEYL remains subject to post-approval regulatory scrutiny, including FDA requirements for dissolution data investigation.

Investor Verification Checklist

• Revenue Sustainability: Verify the trajectory of ZUNVEYL product sales and the extent of formulary coverage with major Pharmacy Benefit Managers (PBMs) and payors.
• Internal Control Remediation: Confirm the status of remediation efforts for the material weakness in financial reporting controls identified in 2025.
• Supply Chain Resilience: Assess the company's contingency plans for its single-source API supplier in Taiwan and U.S. tablet manufacturer.
• Cash Burn Rate: Monitor the rate of cash consumption against the $66.1 million cash balance to validate the 12-month runway estimate.
• Licensing Milestones: Track progress on the CMSI agreement to determine the probability of achieving the $11 million in development/regulatory milestones and $30 million in sales milestones.